Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double-blinded trial in men with cirrhosis of Testosterone therapy versus placebo to assess the impact on body composition

Trial Profile

A randomised, double-blinded trial in men with cirrhosis of Testosterone therapy versus placebo to assess the impact on body composition

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Testosterone undecanoate (Primary) ; Testosterone
  • Indications Hormone deficiency
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Results assessing published in the Journal of Hepatology
    • 13 Jun 2016 Primary endpoint has been met. (Muscle mass =appendicular lean muscle mass (kg) as assessed by body composition component of DEXA (dual energy xray absorptiometry) scanning), as per results published in the Journal of Hepatology.
    • 13 Jun 2016 Results published in the Journal of Hepatology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top